Page last updated: 2024-12-07

3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SDZ EAA 494: N-methyl-D-aspartate receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6437356
CHEMBL ID224678
SCHEMBL ID726553
MeSH IDM0179553

Synonyms (18)

Synonym
3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid
sdz eaa 494
2-piperazinecarboxylic acid, 4-(3-phosphono-2-propenyl)-
cppene
CHEMBL224678
4-[(e)-3-phosphonoprop-2-enyl]piperazine-2-carboxylic acid
137424-80-7
4-[(2e)-3-phosphonoprop-2-en-1-yl]piperazine-2-carboxylic acid
d-ccpene
gtpl4170
SCHEMBL726553
(e)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid
J-003616
4-[(2e)-3-phosphono-2-propen-1-yl]-2-piperazinecarboxylic acid
Q6841079
2-piperazinecarboxylicacid,4-(3-phosphono-2-propen-1-yl)-
132014-88-1
DTXSID001179674

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Recent clinical trials with non-competitive and competitive N-methyl-D-aspartate (NMDA) receptor antagonists in patients with stroke have shown that these patients develop more adverse effects, particularly psychomimetic effects such as hallucinations and agitation, than normal volunteers at equivalent doses."( Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats.
Löscher, W; Szabo, L; Wlaź, P, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Using this pretreatment interval, a dose-response relationship for blocking handling-induced, strychnine-potentiated convulsions was generated for each compound."( Antagonism of non-NMDA receptors inhibits handling-induced, strychnine-potentiated convulsions.
McAllister, KH, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.04000.00030.86666.6900AID282421
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.04000.00030.68056.6900AID282421
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.04000.00030.70716.6900AID282421
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.04000.00030.81966.6900AID282421
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.04000.00030.70726.6900AID282421
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.04000.00030.70726.6900AID282421
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.04000.00030.70726.6900AID282421
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID282421Displacement of [3H]CPP from rat brain NMDA receptor2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological characterization of novel, potent NMDA receptor antagonists.
AID282427Anticonvulsant activity in ip dosed DBA/2 mouse assessed as inhibition of clonic seizures2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological characterization of novel, potent NMDA receptor antagonists.
AID282428Anticonvulsant activity in ip dosed DBA/2 mouse assessed as inhibition of tonic extension seizures2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Design, synthesis, and pharmacological characterization of novel, potent NMDA receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's89 (78.76)18.2507
2000's20 (17.70)29.6817
2010's4 (3.54)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.71%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.85%)4.05%
Observational0 (0.00%)0.25%
Other114 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]